Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EKTAY Elekta AB (publ)	$4.96 -3.6%	$5.06	$4.36 ▼ $7.13	$1.90B	1.22	16,436 shs	8,933 shs
GH Guardant Health	$49.29 +0.6%	$43.72	$20.14 ▼ $52.92	$6.11B	1.37	2.13 million shs	1.94 million shs
RDNT RadNet	$55.41 -2.1%	$54.99	$45.00 ▼ $93.65	$4.16B	1.43	690,300 shs	705,671 shs
VCYT Veracyte	$26.44 -0.9%	$29.44	$19.73 ▼ $47.32	$2.07B	2.09	912,674 shs	953,596 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EKTAY Elekta AB (publ)	0.00%	-3.79%	-7.21%	-11.49%	-22.58%
GH Guardant Health	0.00%	+2.56%	+21.82%	+14.92%	+54.81%
RDNT RadNet	0.00%	-5.52%	-8.05%	+19.06%	-10.27%
VCYT Veracyte	0.00%	-3.71%	-7.20%	-16.09%	+19.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EKTAY Elekta AB (publ)	3.8365 of 5 stars	0.0	5.0	1.7	0.0	2.1	1.7	3.1
GH Guardant Health	3.7384 of 5 stars	2.5	3.0	0.0	4.3	2.0	2.5	0.6
RDNT RadNet	4.1882 of 5 stars	3.8	2.0	0.0	4.6	2.9	2.5	0.0
VCYT Veracyte	4.0674 of 5 stars	4.4	1.0	0.0	4.3	2.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EKTAY Elekta AB (publ)	2.00	Hold	N/A	N/A
GH Guardant Health	3.00	Buy	$53.76	9.07% Upside
RDNT RadNet	3.50	Strong Buy	$69.60	25.61% Upside
VCYT Veracyte	2.70	Moderate Buy	$40.90	54.69% Upside

Current Analyst Ratings Breakdown

Latest EKTAY, GH, RDNT, and VCYT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/13/2025	GH Guardant Health	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$60.00 ➝ $65.00
6/13/2025	RDNT RadNet	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$69.00
6/12/2025	RDNT RadNet	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/3/2025	EKTAY Elekta AB (publ)	Danske Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/8/2025	VCYT Veracyte	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$49.00 ➝ $42.00
5/8/2025	VCYT Veracyte	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $41.00
5/6/2025	GH Guardant Health	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $60.00
5/5/2025	GH Guardant Health	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/5/2025	GH Guardant Health	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$52.00 ➝ $57.00
5/1/2025	GH Guardant Health	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $65.00
5/1/2025	GH Guardant Health	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$56.00 ➝ $60.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EKTAY Elekta AB (publ)	$1.70B	1.12	$0.50 per share	9.86	$2.64 per share	1.88
GH Guardant Health	$774.00M	7.89	N/A	N/A	$1.34 per share	36.78
RDNT RadNet	$1.87B	2.22	$2.95 per share	18.81	$11.79 per share	4.70
VCYT Veracyte	$463.39M	4.47	$0.06 per share	442.29	$14.30 per share	1.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EKTAY Elekta AB (publ)	$122.52M	$0.05	19.82	11.52	N/A	5.65%	11.07%	3.70%	8/27/2025 (Estimated)
GH Guardant Health	-$479.45M	-$3.39	N/A	N/A	N/A	-59.05%	-19,157.20%	-25.96%	8/6/2025 (Estimated)
RDNT RadNet	$3.04M	-$0.43	N/A	104.55	N/A	-0.25%	4.29%	1.45%	8/6/2025 (Estimated)
VCYT Veracyte	-$74.40M	$0.41	N/A	36.72	N/A	-2.18%	3.02%	2.80%	8/5/2025 (Estimated)

Latest EKTAY, GH, RDNT, and VCYT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/28/2025	Q4 2025	EKTAY Elekta AB (publ)	$0.13	$0.11	-$0.02	-$0.10	$507.19 million	$503.22 million
4/30/2025	Q1 2025	GH Guardant Health	-$0.57	-$0.49	+$0.08	-$0.77	$189.91 million	$203.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EKTAY Elekta AB (publ)	$0.11	2.22%	N/A	220.00%	N/A
GH Guardant Health	N/A	N/A	N/A	N/A	N/A
RDNT RadNet	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EKTAY Elekta AB (publ)	0.60	1.05	0.81
GH Guardant Health	N/A	6.22	5.85
RDNT RadNet	0.89	2.16	2.16
VCYT Veracyte	N/A	5.08	4.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EKTAY Elekta AB (publ)	N/A
GH Guardant Health	92.60%
RDNT RadNet	77.90%
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
EKTAY Elekta AB (publ)	41.28%
GH Guardant Health	6.10%
RDNT RadNet	5.60%
VCYT Veracyte	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EKTAY Elekta AB (publ)	4,718	383.57 million	225.23 million	Not Optionable
GH Guardant Health	1,790	123.89 million	116.76 million	Not Optionable
RDNT RadNet	8,970	75.03 million	70.24 million	Optionable
VCYT Veracyte	790	78.32 million	76.49 million	Optionable

EKTAY, GH, RDNT, and VCYT Headlines

Recent News About These Companies

Veracyte (NASDAQ:VCYT) Rating Increased to Buy at Wall Street Zen

June 15 at 4:13 AM | americanbankingnews.com

Veracyte, Inc. (NASDAQ:VCYT) Shares Purchased by Assenagon Asset Management S.A.

June 14 at 4:21 AM | marketbeat.com

Veracyte (NASDAQ:VCYT) Stock Rating Upgraded by Wall Street Zen

June 14 at 2:16 AM | marketbeat.com

Veracyte (NASDAQ:VCYT) Shares Down 4.8% - Should You Sell?

June 12 at 4:58 PM | marketbeat.com

Veracyte (VCYT) Fell Despite Reporting Revenue Growth and Improved Profitability

June 9, 2025 | msn.com

Cathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D Systems

June 7, 2025 | benzinga.com

Insider Selling: John Leite Sells Shares of Veracyte Inc (VCYT)

June 6, 2025 | gurufocus.com

Veracyte (VCYT) Down 13.6% Since Last Earnings Report: Can It Rebound?

June 6, 2025 | msn.com

Cathie Wood’s ARK sells Palantir and Roblox, buys Veracyte and Guardant

June 4, 2025 | investing.com

Veracyte (VCYT) Shares Pulled Back Despite Beating Expectations

June 3, 2025 | msn.com

Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by AEGON ASSET MANAGEMENT UK Plc

June 3, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 30,059 Shares of Veracyte, Inc. (NASDAQ:VCYT)

June 2, 2025 | marketbeat.com

Veracyte (NASDAQ:VCYT) Lowered to Hold Rating by Wall Street Zen

June 2, 2025 | marketbeat.com

Quent Capital LLC Has $337,000 Stake in Veracyte, Inc. (NASDAQ:VCYT)

June 1, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Purchases New Stake in Veracyte, Inc. (NASDAQ:VCYT)

June 1, 2025 | marketbeat.com

Veracyte, Inc. (NASDAQ:VCYT) Given Average Rating of "Moderate Buy" by Brokerages

May 30, 2025 | marketbeat.com

Voloridge Investment Management LLC Reduces Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)

May 29, 2025 | marketbeat.com

Veracyte, Inc. (VCYT) Presents Breakthrough Genomic Data to Predict Cancer Therapy Response at ASCO

May 29, 2025 | insidermonkey.com

Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

May 28, 2025 | businesswire.com

Veracyte: Upgrading To Neutral

May 26, 2025 | seekingalpha.com

Palisades Investment Partners LLC Acquires New Position in Veracyte, Inc. (NASDAQ:VCYT)

May 24, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Among the Market’s Most Shorted: 2 Firms With +40% Short Interest
By Leo Miller | June 3, 2025
View Among the Market’s Most Shorted: 2 Firms With +40% Short Interest
Why Super Micro Computer's Upside Could Trigger a Short Squeeze
By Gabriel Osorio-Mazilli | June 3, 2025
View Why Super Micro Computer's Upside Could Trigger a Short Squeeze
Super Micro Computer Stock Clears New Path Higher on Saudi Orders
By Gabriel Osorio-Mazilli | May 22, 2025
View Super Micro Computer Stock Clears New Path Higher on Saudi Orders

EKTAY, GH, RDNT, and VCYT Company Descriptions

Elekta AB (publ) OTCMKTS:EKTAY

$4.96 -0.18 (-3.60%)

As of 06/13/2025 03:37 PM Eastern

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Guardant Health NASDAQ:GH

$49.29 +0.27 (+0.55%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$48.66 -0.63 (-1.29%)

As of 06/13/2025 07:52 PM Eastern

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

RadNet NASDAQ:RDNT

$55.41 -1.17 (-2.07%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$55.42 +0.01 (+0.02%)

As of 06/13/2025 05:42 PM Eastern

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

Veracyte NASDAQ:VCYT

$26.44 -0.25 (-0.94%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$26.44 -0.01 (-0.02%)

As of 06/13/2025 04:44 PM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time